Featured Research

from universities, journals, and other organizations

Nomadic Outposts Of Transplanted Stem Cells Tracked In Stanford Study

Date:
December 16, 2003
Source:
Stanford University Medical Center
Summary:
Doctors regularly inject stem cells into patients whose bone marrow has been destroyed by chemotherapy or radiation, but they haven't known where these cells go after being injected.

STANFORD, Calif. - Doctors regularly inject stem cells into patients whose bone marrow has been destroyed by chemotherapy or radiation, but they haven't known where these cells go after being injected. Research at the Stanford University School of Medicine has yielded an unexpected answer: when injected into mice, these cells may set up camp in one tissue early on but then move to another location or disappear entirely.

Published in the Dec. 15 online edition of the Proceedings of the National Academies of Science, the work upsets current thinking that transplanted stem cells find a habitable niche, settle in for the long haul and begin producing new blood cells. Instead, the newly transplanted cells drift throughout the body, nestling in one of a few homes where their populations subsequently wax and wane until some finally flourish.

Researchers said the procedure used to follow the injected cells' movements could one day help scientists hone their techniques for transplanting bone-marrow stem cells in humans and optimize therapies for cancer and immunodeficiencies. Developing these types of new stem cell-based treatments for cancer is among the primary goals of Stanford's Institute for Cancer/Stem Cell Biology and Medicine.

Yu-An Cao, PhD, a research associate and first author of the paper, said that until now injecting bone-marrow stem cells into a patient was like injecting them into a black box. "We didn't know where those cells were going," he said. Watching the fates of these cells after transplantation had raised more questions than it answered. He said in testing a new protocol, they now can watch to see whether the cells proliferate more quickly or if the patterns of inhabitation are altered.

"We are really curious about what is happening," Cao said. "We want to know why the process is so dynamic with unpredictable fates for the initial stem cell foci. There's no obvious reason for the stem cells to leave what appears to be a perfectly good place to homestead and proliferate."

Eventually, the work also could help guide transplantation procedures using other types of stem cells. Cao said an upcoming experiment will use the same technique to monitor transplanted neuronal stem cells. "We can monitor the fate of those stem cells and help evaluate transplantation protocols," he said. This type of approach could speed the development of stem cell transplantation therapies for disorders such as Parkinson's disease.

Cao and Christopher Contag, PhD, assistant professor of pediatrics, radiology, microbiology and immunology, and lead author of the paper, were able to follow the transplanted cells' travels because they all made a firefly protein called luciferase. This protein produces a dim light when it comes in contact with another molecule called luciferin. Unlike fireflies, mice don't normally make luciferin, but the recipient mice received doses of the molecule throughout the experiment. Once injected into the recipient mice - whose bone marrow had been destroyed by radiation - the luciferase-producing transplanted cells produced a faint glow. Like a campfire at a new settlement, this dim light pinpointed the cells' location.

Although the light from luciferase isn't bright enough to see by eye, an ultrasensitive video camera originally developed by Contag can detect the faint light and show researchers where the glowing cells have settled. The experiment highlighted a handful of stem cell resting places, including the spleen and the bone marrow in the vertebrae, thighbone, shinbone, skull, ribs and sternum, where stem cells were already known to produce new blood cells.

Of all the locations, the spleen and the vertebrae were the two most likely sites for the new cells to settle. These are also the two roomiest compartments, according to Contag. "Where the cells go initially seems to relate to the size of the compartment and its openness," he said. If that location contained existing stem cells, the transplanted stem cell would detect signals indicating, "this compartment is full, we don't want you here," he added. An empty compartment probably lacks these unwelcoming signals. "The cell knows there's an empty seat to jump into, and now we can watch them play musical chairs - we just don't hear the music yet."

What surprised the researchers is how much the pattern varied. In many cases one location would initially house a healthy population of glowing stem cells, only to have that population fade over time while daughter cells set up camp at a distant location. In other mice, locations that initially contained a languishing population of cells would suddenly flourish. When the researchers took stem cells from sites within one transplanted animal and put them into a second mouse lacking bone marrow, those stem cells once again seemed to take a random path to new niches and started the game of musical chairs over again. "This shows that the niche preferences aren't programmed into the cells," Contag said.

Other Stanford researchers who contributed the work include postdoctoral scholars Amy Wagers, PhD, and Andreas Beilhack, PhD; technician Joan Dusich; research associate Michael Bachmann, MD, DSc; Robert Negrin, MD, associate professor of medicine; and Irving Weissman, MD, the Karel and Avice Beekhuis Professor of Cancer Biology and director of Stanford's Institute for Cancer/Stem Cell Biology and Medicine.

Contag is one of the founders of Xenogen, which makes the sensitive video camera used in this study.

###

Stanford University Medical Center integrates research, medical education and patient care at its three institutions - Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children's Hospital at Stanford. For more information, please visit the Web site of the medical center's Office of Communication & Public Affairs at http://mednews.stanford.edu.


Story Source:

The above story is based on materials provided by Stanford University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Stanford University Medical Center. "Nomadic Outposts Of Transplanted Stem Cells Tracked In Stanford Study." ScienceDaily. ScienceDaily, 16 December 2003. <www.sciencedaily.com/releases/2003/12/031216074848.htm>.
Stanford University Medical Center. (2003, December 16). Nomadic Outposts Of Transplanted Stem Cells Tracked In Stanford Study. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2003/12/031216074848.htm
Stanford University Medical Center. "Nomadic Outposts Of Transplanted Stem Cells Tracked In Stanford Study." ScienceDaily. www.sciencedaily.com/releases/2003/12/031216074848.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins